Enhanced RAS signaling and decreased androgen dependence of prostate cancer cells accompany poor clinical outcomes. Elevated autocrine fibroblast growth factors 2 (FGF-2) signaling promotes prostate cancer cell growth and survival. Expression of lysyl oxidase (LOX) inhibits RAS transforming activity. LOX is secreted as 50 kDa pro-LOX protein and then undergoes extracellular proteolytic processing to form B30 kDa LOX enzyme and B18 kDa propeptide (LOX-PP). We have previously shown that LOX-PP inhibits breast cancer cell transformation and tumor formation, but mechanisms of action of LOX-PP have not been fully elucidated. Here we report that LOX expression is reduced in prostate cancer cell lines and that recombinant LOX-PP protein inhibits serum-stimulated DNA synthesis and MEK/ERK and PI3K/AKT pathways in DU 145 and PC-3 androgenindependent cell lines. In DU 145 cells, treatment with a pharmacologic FGF-receptor inhibitor or a neutralizing anti-FGFR1 antibody mimicked LOX-PP inhibition of serum-stimulated DNA synthesis. FGF-2-stimulated DNA synthesis, ERK1/2, AKT and FRS2a activation were found all to be inhibited by LOX-PP in DU 145 cells. LOX-PP reduced specific binding of FGF-2 to DU 145 cells, suggesting that LOX-PP targets FGF signaling at the receptor. Interestingly, PC-3 cells did not respond to FGF-2, consistent with previous reports. We conclude that LOX-PP inhibits proliferation of DU 145 cells by interfering with FGFR(s) binding and signaling, and that LOX-PP has other mechanisms of action in PC-3 cells.
Introduction
Prostate cancer is a leading cause of cancer-related deaths in men (Samid et al., 1993) . Prostate cancer initially requires androgen for growth and responds to hormone ablation strategies (castration and/or antiandrogen). Disease progresses to a state of reduced hormone dependence for which there is no effective treatment (Weber and Gioeli, 2004) . RAS signaling is activated in advanced prostate cancer (Erlich et al., 2006) . Activation of mitogen-activated protein (MAP) kinases via RAS correlates positively with prostate cancer progression and drives androgen independence (Gioeli et al., 1999) . A RAS antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vivo (McPherson et al., 2004) . Activation of RAS signaling is sufficient for progression of androgen-dependent LNCaP and CWR22 cells toward androgen independence (Weber and Gioeli, 2004) . RAS signaling is highly active in androgen-independent DU 145 and PC-3 cell lines (Gioeli et al., 1999) , and overexpressed Her-2/neu plays a major role in growth by elevating RAS activity (Kominsky et al., 2000) . Activating RAS mutations are rare in prostate cancer (Erlich et al., 2006) , suggesting that RAS activation predominantly occurs through growth factor receptor activation (Culig et al., 1994; Planz et al., 2001) .
Fibroblast growth factors (FGFs) play an important role in growth and maintenance of normal prostate tissues (Ropiquet et al., 2000) . FGFs are produced by stromal cells and contribute to paracrine stimulation of epithelial growth . In particular, FGF-2 has a major role in prostate epithelial cell proliferation . FGF-2 antisense studies in prostate cancer cell lines show that FGF-2 is required for cell survival and proliferation (Shain, 2004) . Effects of FGFs are mediated by binding to high-affinity cell surface receptors (Nugent and Edelman, 1992; Johnson and Williams, 1993; Natke et al., 1999; Powers et al., 2000; Forsten-Williams et al., 2005) . Binding of FGF-2 to its receptors (FGFR1-4) is enhanced by cell surface heparan sulfate proteoglycans and leads to FGFRs autophosphorylation and activation (Johnson and Williams, 1993; Nugent and Iozzo, 2000) . Ultimately, activation of FGFRs leads to signal transduction through multiple pathways downstream of activated RAS including ERK MAP kinases, the AKT/phosphoinositol 3-kinase (PI3K) pathway, and by FGF receptor substrate-2a (FRS2a), an FGF pathway-specific mediator (Mohammadi et al., 1991; KwabiAddo et al., 2004; Schlessinger, 2004; Weber and Gioeli, 2004; Eswarakumar et al., 2005) . Androgen-independent DU 145 and PC-3 cell lines express higher amounts of FGFR1 compared to androgen-independent LNCaP cells (Nakamoto et al., 1992) . Unlike DU 145 cells, however, PC-3 cells are both unresponsive to exogenous FGF-2 and express higher levels of c-MYC (Nakamoto et al., 1992; Jones et al., 1997) .
Lysyl oxidase (LOX) enzyme catalyses the final enzymatic step required for collagen and elastin crosslinking Kagan and Li, 2003) . LOX is synthesized as a 50 kDa glycosylated proenzyme (Pro-LOX), and then secreted where it undergoes extracellular proteolytic processing by procollagen C-proteinases to functional B30 kDa enzyme and an B18 kDa propeptide (LOX-PP; Trackman et al., 1992; Uzel et al., 2001; Kagan and Li, 2003) . Generation of LOX enzyme and LOX-PP occurs as a consequence of extracellular posttranslational biosynthetic proteolytic processing of secreted Pro-LOX (Trackman et al., 1992) .
Expression of the LOX gene was found to inhibit RAS transforming activity and was hence named the 'ras recision' gene (rrg; Contente et al., 1990; Kenyon et al., 1991) . Reduced LOX levels were observed in many cancers and cancer-derived cell lines (Kuivaniemi et al., 1986; Contente et al., 1990; Krzyzosiak et al., 1992; Hajnal et al., 1993; Hamalainen et al., 1995) . Furthermore, LOX expression is reduced in primary and metastatic prostate cancers (Ren et al., 1998) . We have reported that LOX-PP, and not LOX enzyme, inhibits RAS-dependent transformation of NIH 3T3 cells (Jeay et al., 2003; Palamakumbura et al., 2004) . LOX-PP is a potent inhibitor of the transformed phenotype of breast cancer cells . Moreover, LOX-PP expression attenuates growth of breast cancer cells implanted into mice . By contrast, active LOX enzyme promotes invasion by some tumor cells (Kirschmann et al., 2002; Payne et al., 2005) suggesting that LOX-PP may function to control negative effects of LOX enzyme with respect to cancer development.
We report here that LOX-PP inhibits growth responses to serum and to FGF-2 of androgenindependent DU 145 prostate cancer cells. A mechanism of action of LOX-PP is shown here for the first time: LOX-PP inhibits FGF-2 binding to DU 145 cells, thereby interrupting autocrine and/or paracrine pathways. Data obtained with PC-3 cells indicate that LOX-PP similarly inhibits serum-stimulated growth responses, but by mechanisms that differ from those in DU 145 cells.
Results

Prostate cancer cells express lower levels of LOX than normal prostate cells
We evaluated LOX expression levels in six different human prostate cancer cell lines and in a control prostate epithelial cell line (PWR-1E). Cells were grown (Bonaccorsi et al., 2004) , total RNA isolated and LOX expression determined by qPCR. All cancer cell lines express less than 10% of LOX mRNA levels compared to PWR-1E prostate epithelial cells (Figure 1a ). To evaluate relative LOX protein expression, conditioned media samples were subjected to western blotting. High levels of B50 kDa pro-LOX protein (Trackman et al., 1992) were detected in conditioned medium from PWR-1E cells (Figure 1b) . In addition, B18 and B35 kDa protein bands were observed in media from PWR-1E cells (Figure 1b) that correspond, respectively, to glycosylated and nonglycosylated forms of LOX-PP previously seen in conditioned media samples (Guo et al., 2007) . No LOX-PP immunoreactive bands were seen in conditioned media samples from any of the six prostate cancer cell lines tested, consistent with findings at the RNA level seen in Figure 1a .
rLOX-PP inhibits growth of prostate cancer cells
We next evaluated the ability of rLOX-PP to inhibit serum-stimulated DNA synthesis of DU 145 and PC-3 cells. rLOX-PP inhibits serum-stimulated thymidine incorporation in both cell lines in a dose-dependent manner compared to controls (Figure 2 ). Figure 1 Real-time qPCR analysis and western analyses show reduced lysyl oxidase (LOX) expression in prostate cancer cells. Cells were cultured, and RNA and media proteins were isolated as described in 'Materials and methods'. (a) Total RNA samples (1 mg) were reverse transcribed and cDNA was subjected to qPCR using Taqman probes (assays On Demand; Applied Biosystems). LOX mRNA levels were calculated relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) levels, and RNA isolated from normal prostate epithelial cells (PWR-1E) cells was used as the normal control RNA. Data are expressed as fold change relative to PWR-1E RNA. (*Po0.05 as determined by ANOVA with Tukey HSD Post Hoc.) (b) Conditioned serum-free media (24 h) from confluent cultures of prostate cell lines were collected, concentrated and protein concentrations determined. Equal amounts of proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and western blotting with anti-LOX-PP antibody. Data are from one representative experiment performed twice. Lanes 1-6: PWR-1E, LNCaP, 22RV1, PC-3, DU 145, CWR22, respectively.
Effects of rLOX-PP on cell cycle regulatory proteins expression was next measured. Serum-stimulated cyclin D1, cyclin-dependent kinase 4 (CDK4), CDK6 and proliferating cell nuclear antigen (PCNA) expression were all decreased by rLOX-PP in a dose-dependent manner (Figure 3 ). That rLOX-PP inhibits serumstimulated expression of these proteins further supports the notion that rLOX-PP interferes with proliferative responses in prostate cancer cells.
rLOX-PP inhibits ERK1/2 and AKT signaling Both DU 145 and PC-3 cells are androgen independent and express high amount of RAS protein. As an index of RAS activity, we determined levels of serum-stimulated phosphorylation of ERK and AKT in the presence and absence of LOX-PP. Data in Figures 4 and 5 demonstrate that serum-stimulated ERK1/2 and AKT phosphorylation is inhibited by rLOX-PP in a dosedependent manner. These data support the notion that rLOX-PP inhibits growth factor-mediated signaling pathways in these cells.
Serum-induced proliferation of prostate cancer cells and FGF-2 signaling
In prostate cancer, wild-type RAS is activated by autocrine and paracrine growth factor regulation (Weber and Gioeli, 2004) , often by FGF-2-dependent pathways Ozen et al., 2001; Gioeli, 2005) . We, therefore, investigated effects of FGF-2 on DNA synthesis of DU 145 and PC-3 cells. FGF-2 increases DNA synthesis of DU 145 cells and is dose dependent (Figure 6a ). However, PC-3 cells did not significantly respond to exogenous FGF-2, consistent with previous reports (Nakamoto et al., 1992; Jones et al., 1997 ; data not shown). Hence, DU 145 cells were employed to further investigate effects of rLOX-PP on FGF-2-stimulated DNA synthesis.
We next investigated whether LOX-PP inhibits serum-stimulated proliferation by interfering with FGF-2-dependent signaling in DU 145 cells. PD173074 is an ATP competitive reversible inhibitor of FGFR kinase that attenuates FGFR1-mediated signaling. DU 145 cells cultured in media containing 0.1% fetal bovine serum (FBS) were treated with 0-200 nM PD173074 for 18 h. These concentrations of PD173074 are known to specifically inhibit FGF-2-induced proliferation (Bansal et al., 2003) . Cells were then stimulated with 10% serum for 6 h and [ 3 H]thymidine incorporation was determined. As shown in Figure 6b , 100 and 200 nM PD173074 inhibit seruminduced DNA synthesis of DU 145 cells, and inhibition is dose dependent.
To confirm that serum-induced proliferation of DU 145 cells depends mostly on FGF receptor-mediated signaling, neutralizing anti-FGFR1 monoclonal antibody (clone VBS1) was used to block FGFR1 activity. This antibody inhibits FGF-2-induced DNA synthesis in coronary venular endothelial cells by blocking FGF-2 binding to its receptor (Blanckaert et al., 2002) . DU 145 cells cultured in 0.1% serum were treated with 0 or 10 mg/ml anti-FGFR1 antibody or control immunoglobulin G for 18 h. Cells were then stimulated with 10% serum for 6 h and [ 3 H]thymidine incorporation was determined. Anti-FGFR1 antibody inhibits seruminduced DNA synthesis (Figure 6c) . Blocking of the anti-FGFR antibody by pretreatment with rFGFR1 diminished its ability to inhibit serum-induced DNA synthesis, confirming the specificity of the anti-FGFR antibody employed (Figure 6c ). Separate experiments show that neutralizing FGFR1 antibody fully blocks FGF-2-stimulated DNA synthesis in DU 145 cells, as expected (Supplementary Figure S1) . rLOX-PP inhibits FGF-2 stimulation of DNA synthesis in DU 145 cells Effects of rLOX-PP on FGF-2-dependent DNA synthesis of DU 145 cells were investigated. Cells grown in serum-free medium containing 0.1% bovine serum albumin (BSA) for 24 h were treated with increasing concentrations of rLOX-PP, and cells were then treated with FGF-2 followed by addition of [ 3 H]thymidine in the absence or continuous presence of rLOX-PP for 6 h. [ 3 H]Thymidine incorporation was then determined. rLOX-PP inhibits FGF-2-stimulated DNA synthesis of DU 145 cells in a dose-dependent manner to levels near nonstimulated control cells (Figure 7 ). Taken together, results suggest that rLOX-PP inhibits FGF-2-induced proliferative responses in DU 145 cells.
rLOX-PP inhibits FGF-2-induced signaling
We next asked whether rLOX-PP can interfere with FGF-2-induced activation of ERK1/2 and AKT. Cells in serum-free media containing 0.1% BSA were treated with rLOX-PP (0 or 10 mg/ml), and then stimulated with 0 or 10 ng/ml FGF-2 for 5 or 15 min. Cell layer proteins Figure 4 Lysyl oxidase propeptide (LOX-PP) inhibits serumstimulated ERK1/2 phosphorylation in DU 145 and PC-3 cells. Cells cultured in media containing 0.1% fetal bovine serum (FBS) for 24 h were treated with rLOX-PP (0, 1, 5 or 10 mg/ml). After 24 h, cells were stimulated with 10% FBS for 15 min, followed by extraction of total cell layer proteins. Equal amounts of proteins from DU 145 (a) and PC-3 (b) were subjected to 10% SDS and western blotting using anti-phospho ERK1/2 antibody and antitotal ERK1/2 antibody for normalization. Results shown are from a representative experiment. (c) Densitometric analysis of ERK1/2 phosphorylation normalized to total ERK1/2 expression. Values are expressed as percent normalized ERK1/2 phosphorylation relative to control cultures lacking rLOX-PP that were stimulated with 10% FBS (as 100%), and data are combined from three independent experiments each performed in triplicate. (*Po0.05 as determined by ANOVA with Tukey HSD Post Hoc.) Figure 5 Lysyl oxidase propeptide (LOX-PP) inhibits serumstimulated AKT phosphorylation in DU 145 and PC-3 cells. Cells cultured in media containing 0.1% fetal bovine serum (FBS) for 24 h were treated with rLOX-PP (0, 1, 5 or 10 mg/ml). After 24 h, cells were stimulated with 10% FBS for 15 min, followed by extraction of total cell layer proteins. Equal amounts of proteins from DU 145 (a) and PC-3 cells (b) were subjected to 10% SDSpolyacrylamide gel electrophoresis (PAGE) and western blotting using anti-phospho AKT antibody and anti-total AKT antibody for normalization. were harvested and analysed by western blotting. As shown in Figure 8 , rLOX-PP strongly inhibits FGF-2-induced ERK1/2 and AKT phosphorylation.
To further confirm that rLOX-PP interferes with FGF-2-induced signaling, effects of rLOX-PP on activating phosphorylations of FRS2a were determined. FRS2a is an FGF pathway-specific signaling intermediate (Eswarakumar et al., 2005) . DU 145 cells grown in serum-free media containing 0.1% BSA were treated with rLOX-PP (0 or 10 mg/ml) followed by 0 or 10 ng/ml FGF-2 for 2 min, when FRS2a phosphorylation is maximum. Cell layer proteins were then harvested and analysed by western blotting. As shown in Figure 9 , rLOX-PP potently inhibits FGF-2-induced FRS2a phosphorylation.
rLOX-PP inhibits binding of FGF-2 to DU 145 cells Binding of FGF-2 to heparan sulfate proteoglycans facilitates its binding to receptors (Chu et al., 2004; Chua et al., 2004) . LOX-PP is rich in arginine and is cationic with a calculated pI of 12.5. Due to its highly basic nature, LOX-PP could potentially interfere with FGF-2 binding to heparan sulfate proteoglycans and/or to FGFRs, and thereby inhibit FGF-2-dependent signaling. Hence, the specific saturation-binding curve of FGF-2 to DU 145 cells was determined by competitive binding assays under equilibrium conditions. Cells cultured in medium containing 0.1% BSA for 24 h were treated with 125 I-FGF-2 (0-600 pM) for 2 h at 4 1C. Bound 125 I-FGF-2 was extracted and quantified using a gamma counter. Nonspecific binding was determined in the presence of excess nonlabeled FGF-2 (230 nM). FGF-2 binding to DU 145 cells reached saturation at concentrations of 350 pM of total FGF-2 (data not shown), a biologically active concentration that corresponds to 6 ng/ml FGF-2 as seen in Figure 6a . This concentration of FGF-2 was then used to determine whether rLOX-PP can inhibit FGF-2 binding to DU 145 cells. Cells were treated with 125 I-FGF-2 and rLOX-PP (0-10 mg/ml) for 15 min, and FGF-2 binding was determined. Data in Figure 10 demonstrate that rLOX-PP inhibits specific binding of FGF-2 in a dosedependent manner. An IC 50 of 6.8 mg/ml was obtained from the same data. This value is consistent with concentrations of LOX-PP required for inhibition of serum-and FGF-2-stimulated activities. Taken together, data show that rLOX-PP inhibition of FGF-2-induced signaling and biological activity in DU 145 cells occurs at the level of inhibition of FGF-2 cell binding in DU 145 cells. 
Discussion
Prostate cancers typically begin as androgen-sensitive lesions but develop into androgen-insensitive lesions with progression to advanced stages (Erlich et al., 2006) . Increases in autocrine and paracrine growth factor loops correlate with prostate cancer progression and with androgen independence (Culig et al., 1994; Weber and Gioeli, 2004) . Increased expression of growth factors including FGF-2, epidermal growth factor (EGF), transforming growth factor-a, keratinocyte growth factor and insulin-like growth factor-1 and increased expression of their respective cognate receptors are responsible for driving progression to androgen independence (Culig et al., 1994; Planz et al., 2001 ). This understanding predicts that a variety of signaling events may drive the transformed phenotype of prostate cancer cells. Interactions between different signaling pathways are likely to change as prostate cancer progresses from androgen dependent to androgen independent.
FGF-2, however, is expressed during all stages of human prostate cancer and plays a critical role in prostate cancer progression KwabiAddo et al., 2004) . Hemi-or homozygous inactivation of FGF-2 alleles in mice with transgenic adenocarcinoma of the prostate by crossing with FGF-2 null mice have increased survival by inhibiting progression to a poorly differentiated tumor cell phenotype and to metastatic disease (Polnaszek et al., 2003) . Higher levels of FGF-2 are expressed by androgen-independent DU 145 and PC-3 cell lines compared to androgen-dependent LNCaP cells (Cronauer et al., 1997) . Hence, it has been suggested that FGF-2 is a major growth factor responsible for increased proliferation and metastasis in prostate cancer cells by paracrine and autocrine pathways.
FGF-2 signaling is an attractive therapeutic target for cancer therapy. Suramin, a compound that can inhibit FGF signaling, was reported to enhance antitumor effect of doxorubicin on human prostate cancer (Zhang et al., 2001) . Moreover, inhibition of export of FGF-2 by Anvirzel, a novel treatment for cancer, contributes to its antitumor activity (Smith et al., 2001) . FGF-2 activation of MEK/ERK signaling plays a critical role in cancer cell migration (Wesley et al., 2005; Hatziapostolou et al., 2006) . In endothelial cells, FGF-2 increases activation of integrin a v b 3 to facilitate cell migration via the ERK pathway (Kwabi-Addo et al., 2004) . Moreover, FGF-2 and PDGF synergistically promote tumor angiogenesis and pulmonary metastasis (Nissen et al., 2007) . Thus, FGF-2/FGFR signaling can play an important role in invasion and migration of cancer cells. Several different approaches have been taken to inhibit FGFR-mediated signaling, such as developing antibodies to target receptors (He et al., 2003) or using small molecule inhibitors that target the catalytic kinase domain (Mohammadi et al., 1997) .
Although LOX-PP reduces cancer cell transformation and inhibits RAS-dependent signaling pathways (Jeay Figure 8 Lysyl oxidase propeptide (LOX-PP) inhibits fibroblast growth factor 2 (FGF-2)-stimulated ERK and AKT phosphorylation in DU 145 cells. Cells grown in medium containing 0.1% bovine serum albumin (BSA) for 24 h were treated with 0 or 10 mg/ml rLOX-PP. After 24 h, cells were treated with 10 ng/ml FGF-2 for 5 min (for ERK1/2) or 15 min (for AKT), followed by extraction of total cell layer proteins. (a) Equal amounts of proteins were subjected to western blotting using antiphospho ERK1/2 or anti-phospho AKT antibody and antitotal ERK1/2 or anti-total AKT antibody for normalization. Results shown are from a representative experiment performed three times with similar results. (b) Densitometric analysis of ERK1/2 and AKT phosphorylation normalized to total ERK1/2 and total AKT expression, respectively. Values are expressed as fold change in normalized ERK1/2 or AKT phosphorylation relative to un-stimulated control cultures lacking rLOX-PP. Data shown are from three independent experiments combined each performed in triplicates. (*Po0.05 as determined by Student's t-test.) Palamakumbura et al., 2004; Min et al., 2007; Wu et al., 2007) , mechanisms by which this occurs have remained largely unknown. Here we show for the first time that LOX-PP inhibits FGF-2-induced signaling in DU 145 prostate cancer cells. Data further indicate that one mechanism by which LOX-PP inhibits cell proliferation is to interfere with binding of FGF-2 to its receptor(s) (Figure 10 ). Findings obtained in PC-3 prostate cancer cells show that LOX-PP effectively inhibits proliferative responses to serum, but this inhibition occurs by a mechanism that appears not to include inhibition of FGF-2 signaling. LOX-PP has recently been shown to interfere with integrin-mediated haptotaxis and FAK activation that is driven by activated EGF-receptor (HER2)-initiated signaling in MDA-MB-231 (human) and NF639 (mouse) breast cancer cell lines (Zhao et al., 2009) . Taken together, data support the notion that LOX-PP acts by more than one mechanism to inhibit growth responses of cancer cells. We suggest that the effectiveness of LOX-PP as a tumor suppressor is related to its ability to work by multiple mechanisms of action, rather than by only one mechanism.
Data indicate that LOX expression is low in several prostate cancer cells compared to a normal prostate epithelial cell line (Figure 1) . We have previously shown that an FGF-2 autocrine pathway decreases expression of LOX in RAS-transformed NIH 3T3 fibroblasts (Palamakumbura et al., 2003) . Thus, increased expression of FGF-2 in DU 145 cells could contribute to low expression of LOX itself by these, and perhaps other, cancer cell lines. It is notable that LOX levels were reported to be diminished in primary human prostate cancer tissues and that LOX expression decreases as a function of prostate cancer progression (Ren et al., 1998) . Taken together with the data presented here, we suggest that high levels of FGF-2 in prostate cancer tissues help to both downregulate LOX expression, and, therefore, LOX-PP levels, and promote tumor cell proliferation (Figure 11 ).
There are some conflicting reports regarding whether LOX is a tumor suppressor or a tumor promoter. Increased expression of LOX under hypoxic conditions correlates with increased invasiveness of breast cancer tumors (Erler and Weaver, 2009; . b-Aminopropionitrile, a specific irreversible inhibitor for LOX enzyme activity, reduces breast cancer metastasis significantly in mice, suggesting that LOX enzyme, and not LOX-PP, is responsible for increased metastasis (Kirschmann et al., 2002; Payne et al., 2005; Erler and Giaccia, 2006; .
Based on western blotting data alone, it has recently been suggested that Pro-LOX, and not LOX-PP, is a tumor suppressor (Contente et al., 2009 ). This study, and previous work, show directly that LOX-PP is active as an inhibitor of prostate, breast, lung and pancreatic tumor cell growth and RAS-dependent signaling Wu et al., 2007) . Moreover, Figure 10 Lysyl oxidase propeptide (LOX-PP) inhibits binding of fibroblast growth factor 2 (FGF-2) to DU 145 cells. Cells grown in medium containing 0.1% bovine serum albumin (BSA) for 24 h were treated with LOX-PP (0, 0.05, 0.1, 0.5, 1, 5 or 10 mg/ml) for 15 min, followed by incubation with labeled 6 ng/ml FGF-2 for 2 h at 4 1C. Bound FGF-2 was released by washing with 1 M NaOH and quantified using a gamma counter. Nonspecific binding was determined in the presence of excess nonlabeled FGF-2 (230 nM) and subtracted from the original values. Values are expressed relative to the specific binding of cultures, which were not treated with rLOX-PP (as 100%), and are averages of three independent cultures grown at the same time. Data shown are from three independent experiments combined each performed in triplicates. (*Po0.05 as determined by ANOVA with Tukey HSD Post Hoc.) Figure 9 Lysyl oxidase propeptide (LOX-PP) inhibits fibroblast growth factor 2 (FGF-2)-stimulated FGF receptor substrate-2a (FRS2a) phosphorylation in DU-145 cells. Cells grown in medium containing 0.1% bovine serum albumin (BSA) for 24 h were treated with 0 or 10 mg/ml rLOX-PP. After 24 h, cells were treated with 10 ng/ml FGF-2 for 2 min followed by extraction of total cell layer proteins. (a) Equal amounts of proteins from DU 145 were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE) and western blotting using anti-phospho FRS2a (Tyr196) LOX-PP expression inhibits breast cancer cell growth in xenografts in vivo . LOX-PP itself, therefore, is clearly active as a tumor suppressor. Data do support that ectopic Pro-LOX expression (that contains the LOX-PP domain) inhibits signaling pathways that contribute to cell transformation Wu et al., 2007) . Processing of Pro-LOX to LOX-PP was, however, not inhibited in these reports, and it is not currently possible to definitively conclude which molecular form of LOX-PP is more active as a tumor suppressor. We suspect, however, that Pro-LOX, that appears to be enzymatically inactive (Trackman et al., 1992) , and free LOX-PP are both active tumor suppressors. This notion raises the possibility that regulation of extracellular proteolytic processing of Pro-LOX and turnover of LOX proteins may contribute to the respective balance between the tumor suppressor function of Pro-LOX and LOX-PP, and promotion of invasion by active LOX enzyme.
Materials and methods
Materials
DU 145 and PC-3 and PWR-1E cells were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). Anti-phospho ERK1/2, anti-ERK1/2, anti-phospho AKT (S473), anti-AKT, anti-b-actin, anti-cyclin D1, anti-PCNA, anti-CDK4, anti-CDK6, anti-phospho-FRS2a(Tyr196), antiphospho-FRS2a(Tyr436) and anti-rabbit secondary antibody were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-FGFR1 monoclonal antibody (clone VBS1) was purchased from Millipore (Billerica, MA, USA). Sterile 7.5% BSA and FBS were purchased from Sigma-Aldrich (St Louis, MO, USA). Human recombinant FGF-2 was purchased from Peprotech (Rocky Hill, NJ, USA). Cell culture media (Dulbecco's Modified Eagle's Medium (DMEM), F12K, RPMI-1640 or keratinocytes serum-free medium and reagents (penicillin and streptomycin)) were purchased from Invitrogen (Carlsbad, CA, USA) and ATCC. [ Cell culture Cells were grown in 100 mm cell culture plates as follows, DU 145 in DMEM, PC-3 in F12K, LNCap, CWR22 and 22RV1 in RPMI 1640, and PWR-1E in keratinocytes serum-free medium. All growth media contained 10% FBS, 100 units/ml penicillin and 100 mg/ml streptomycin. Cultures were incubated at 37 1C in a fully humidified atmosphere of 5% CO 2 in air. Cells in logarithmic growth phase were dissociated with trypsin/EDTA, and plated at a desired density. After cells became 75% confluent, they were serum starved for 24 h and then treated as described in each experiment.
RNA isolation and real-time PCR
Total RNA was isolated from PWR-1E, LNCaP, CWR22, 22RV1, DU 145 and PC-3 cell cultures grown in complete media, and purified using RNeasy mini-RNA purification kits (Qiagen, Valencia, CA, USA). RNA samples (1 mg each) were added to 30 ml of reverse transcription (RT) reactions using random primers and Applied Biosystems' Reverse Transcription kit. Thermal cycler conditions for RT were 25 1C for 10 min, 37 1C for 60 min, and 95 1C for 5 min. Portions of 2 ml of each RT reaction were used per 25 ml of real-time PCR (qPCR) reactions. TaqMan probes (Applied Biosystems, Foster City, CA, USA) for LOX (Catalog no. Hs00942480_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Catalog no. Hs99999905_m1) were used in qPCR analyses performed in an Applied Biosystems' GeneAmp Prism 7500 System. Data were analysed using the 2 ÀDDct method (Huggett et al., 2005) and mRNA levels were normalized to GAPDH mRNA.
Expression and purification of LOX-PP Recombinant LOX-PP (rLOX-PP) was expressed and purified to homogeneity from TREX 293 cells as described (Hurtado et al., 2008) .
DNA synthesis assay
Cells grown in 12-well plates were serum-starved for 24 h and then treated according to each experimental condition. Proliferation was induced with serum (10%) or FGF-2 (10 ng/ml) followed by incubation with 2 mCi/ml [ 3 H]thymidine for 6-(for DU 145 cells) or 16 h (PC-3 cells). Experiments were terminated by washing cells with ice cold PBS, followed by 10% trichloroacetic acid. DNA was extracted with 0.2 M NaOH, 0.1% SDS (Bonaccorsi et al., 2004) . Incorporated radioactivity was measured by liquid scintillation counting. Figure 11 Proposed model for inhibition of fibroblast growth factor 2 (FGF-2) signaling and proliferation by lysyl oxidase propeptide (LOX-PP) in DU 145 cells. FGF-2 autocrine signaling is elevated in prostate cancer, and hence FGF-2 signaling is seen to be abnormally high in prostate cancer cells. FGF-2 uniquely phosphorylates and activates FGF receptor substrate-2a (FRS2a), followed by RAS, AKT and ERK mitogen-activated protein (MAP) kinase-dependent signaling resulting in an elevated proliferative response and tumor growth. Pro-LOX is synthesized and secreted as a 50 kDa proenzyme from stromal cells or from other nontransformed epithelial cells, or from tumor cells under hypoxic conditions, and levels of Pro-LOX production in prostate cancer epithelium may decrease as a function of prostate cancer progression (Ren et al., 1998) . Therefore, as prostate cancer progresses, levels of LOX-PP may decline. LOX-PP, either as free LOX-PP after procollagen C-proteinases processing, or possibly as intact 50 kDa LOX proenzyme, when expressed, inhibits FGF-2 binding and signaling, and FGF-2 stimulated proliferation of tumor cells.
Western blotting
Proteins were extracted from cell layers with sample buffer (0.1 M Tris-HCl, 4% SDS, 10% glycerol, 5% b-mercaptoethanol).
In selected experiments, 24 h-conditioned serum-free media samples were collected and concentrated using Amicon Ultra concentrators (Millipore). Protein concentrations were determined using Nano Orange assay kits (Molecular Probes, Eugene, OR, USA). Equal amounts of each sample were then subjected to 10% SDSpolyacrylamide gel electrophoresis and western blotting as described for each experiment. Signals were quantitated using a digital densitometry system (Versadoc; BioRad, Eugene, OR, USA). I-Bolton-Hunter reagent was conducted as previously published (Nugent and Edelman, 1992; Richardson et al., 1999) . Equilibrium binding was measured in cultures at 4 1C in binding buffer (DMEM, low glucose, with 25 mM HEPES, pH 7.2 and 0.1% BSA; Nugent and Edelman, 1992; Fannon and Nugent, 1996) . Cultures were incubated for 2 h at 4 1C with 125 I-FGF-2 and rinsed with binding buffer. Bound FGF-2 was released by washing with 1N NaOH and quantified using a Cobra II auto-gamma 5005 counter (Packard Instruments, Meridian, CT, USA). To determine effects of LOX-PP on FGF-2 binding, DU 145 cells were cultured in media containing 0.1% BSA for 24 h.
Cells were then treated with rLOX-PP (0-10 mg/ml) for 15 min, followed by incubation with 125 I-FGF-2 (350 pM) for 2 h at 4 1C. Bound FGF-2 was then released and quantified. Nonspecific binding was determined in the presence of excess of nonlabeled FGF-2 (230 nM).
Statistics
Statistical tests were performed using the Student's t-test assuming equal variances or one-way ANOVA with Tukey HSD Post Hoc analysis using SPSS software, as indicated in figure Legends.
